Navigation Links
The Bridge Health Recovery Center Announces Upcoming Sessions
Date:4/9/2008

Each of The Bridge's sessions last three weeks and is held at a beautiful retreat adjacent to the majestic canyons of Zion National Park. The Spring session schedule is:

April 28th - May 16th

May 26th - June 13th

June 23rd - July 11th

For more information about The Bridge and the upcoming sessions, please go to http://www.thebridgerecoverycenter.com/sessions.html or call (877) 885-9567.

About The Bridge

The Bridge Recovery Health Center is located in the scenic red rock country of southern Utah. For more information see http://www.thebridgerecoverycenter.com, or call (877) 885-9567.


'/>"/>
SOURCE The Bridge Health Recovery Center
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. LCA-Vision Announces the Opening of its 76th LasikPlus(R) Vision Center in Woodbridge, New Jersey
2. First Health Plans Receive Bridges to Excellence Endorsement and Certification
3. MeadWestvaco and Autism Society of America Launch 2008 ASA Autism Awareness Cambridge Planner
4. 4th annual Templeton-Cambridge fellowships awarded to 10 noted journalists
5. Concentric Medical Names Kimberly Bridges as Vice President of Sales, Announces Receipt of $15 Million Growth Funding
6. Free Book: Critically Acclaimed Book on Anger Management Now Available in Both Unabridged Audio and Print Form Worldwide
7. Bridges to Excellence Launches Medical Home Program
8. Bridges to Excellence Announces New Implementation Programs for Health Plans and Additions to Board of Directors
9. Thoratec Announces Unanimous FDA Advisory Panel Recommendation for Approval of HeartMate II(R) for Bridge-to-Transplantation
10. The Cambridge Group Names Two New Principals
11. Massachusetts Employers and Health Plans Continue to Support Quality Care by Rewarding Physicians through Bridges to Excellence Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... study in East Asian women has identified three genetic ... The research, led by Vanderbilt University investigators, was published ... While breast cancer is one of the most common ... risk factors for the disease have focused on women ... heritage and environmental exposures between East Asian women and ...
(Date:7/23/2014)... July 23, 2014 Five years ago, when ... there were few options for babies diagnosed with a medical ... travel across the country for innovative fetal therapies. Since then, ... Institute to care for their babies in the womb, and ... interventions. , “A number of the babies we see ...
(Date:7/23/2014)... Dennis Thompson HealthDay Reporter , ... with salt is associated with double the risk of heart ... risk skyrockets even higher among those whose diabetes isn,t well-managed, ... people with diabetes who consumed an average of 5.9 grams ... disease than those who consumed, on average, 2.8 grams of ...
(Date:7/23/2014)... San Jose, California (PRWEB) July 23, 2014 ... – Biocompatible materials are biodegradable substances exclusively developed ... to repair or replace diseased body tissues. These ... tissue rejection by the host. Global market for ... driven by factors such as technological advancements and ...
(Date:7/23/2014)... Jose, California (PRWEB) July 23, 2014 ... Packaging plays a vital role in the marketing ... product from damage to influencing customers’ purchase decision. ... brand/product differentiation. Intelligent and efficient packaging provides ample ... to invest in advanced packaging technologies such as ...
Breaking Medicine News(10 mins):Health News:Vanderbilt-led study identifies genes linked to breast cancer in East Asian women 2Health News:St. Louis Fetal Care Institute Marks Five Years of Life Changing Care and Fetal Surgery 2Health News:High-Salt Diets Could Double Risk of Heart Woes for Diabetics 2Health News:High-Salt Diets Could Double Risk of Heart Woes for Diabetics 3Health News:Surge in R&D Investments to Drive the Global Biocompatible Materials Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Surge in R&D Investments to Drive the Global Biocompatible Materials Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Increasing Focus on Packaging as a Marketing Tool Drives the Blister & Other High Visibility Packaging Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Increasing Focus on Packaging as a Marketing Tool Drives the Blister & Other High Visibility Packaging Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Increasing Focus on Packaging as a Marketing Tool Drives the Blister & Other High Visibility Packaging Market, According to New Report by Global Industry Analysts, Inc. 4
... By Randy Dotinga HealthDay Reporter , THURSDAY, ... more evidence that people infected with HIV, the virus that ... as other patients when they undergo kidney transplants. Up ... to HIV patients because of fear that AIDS would quickly ...
... hosting an event on World Aids Day, bringing together some ... future projections for the AIDS pandemic., The panel speakers are ... of Hygiene & Tropical Medicine and former Executive Director of ... Larson, Director of aids2031, an independent consortium set up by ...
... HealthDay Reporter , THURSDAY, Nov. 18 (HealthDay News) ... procedure, can be made more precise by combining a ... Researchers found that a femtosecond laser, used for many ... tissue more cleanly and accurately than manual cataract surgery, ...
... Reporter , WEDNESDAY, Nov. 17 (HealthDay News) -- Using the ... that doctors, prescribing patterns vary across the country in response ... Administration. The result is that patients may be ... live, the researchers said. "We were looking at the ...
... a cardiomyopathy about which little is fully understood, is ... according to a study to be presented Nov. 17 ... in Chicago. The researchers also will report that advanced ... to progress over time in patients with LVNC. ...
... international, multi-center study has revealed the discovery of a novel ... form of eye cancer. Researchers have isolated an oncogene called ... than 40 percent of tumor samples taken from patients with ... November 17, 2010 in the New England Journal of ...
Cached Medicine News:Health News:HIV Patients Do Well After Kidney Transplants: Study 2Health News:HIV Patients Do Well After Kidney Transplants: Study 3Health News:AIDS: Taking a long-term view 2Health News:Study Reports More Precise Way to Remove Cataracts 2Health News:Study Reports More Precise Way to Remove Cataracts 3Health News:Despite FDA Warning, Avandia Use Varies Across U.S. 2Health News:Despite FDA Warning, Avandia Use Varies Across U.S. 3Health News:Cardiac MR sheds light on obscure heart muscle condition 2Health News:Novel genetic mutation that causes the most common form of eye cancer discovered 2
(Date:7/23/2014)... 2014  Nonin Medical, Inc., the inventor of finger ... announced today that Mark VanderWerf , Nonin,s Vice ... of the American Telemedicine Association,s (ATA) Industry Council and ... The ATA is the leading international resource and advocate ... ATA and its diverse membership work to transform healthcare ...
(Date:7/23/2014)... PLYMOUTH MEETING, Pa. , July 23, ... MKT: INO) today announced successful results from ... of VGX-3100 in women with biopsy-proven cervical ... papillomavirus (HPV) types 16 or 18. Treatment ... histopathological regression of CIN2/3 to CIN1 or ...
(Date:7/23/2014)... July 23, 2014  Lightlake Therapeutics Inc. ("Lightlake") ... based on its expertise in opioid antagonists, announced ... drug application ("IND") with respect to its naloxone-based ... today that it has received an additional commitment ... part of the National Institutes of Health ("NIH"), ...
Breaking Medicine Technology:Nonin Medical Announces that Mark VanderWerf has been Elected Chairman of the American Telemedicine Association's Industry Council 2Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 2Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 3Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 4Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 5Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 2Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 3
... Diagnostics Incorporated (NYSE: DGX ), the world,s ... that for the third quarter ended September 30, 2010, ... $1.13 per diluted share, from $192 million, or $1.02 ... Third quarter 2010 results include a benefit of $0.08 ...
... Stryker Corporation (NYSE: SYK ) reported operating ... Third Quarter Highlights ... as reported) to $1,768 million Orthopaedic Implants sales increased ... MedSurg Equipment sales increased 16.3% on a constant currency ...
Cached Medicine Technology:Quest Diagnostics Reports Third Quarter 2010 Financial Results; Updates Guidance for 2010 2Quest Diagnostics Reports Third Quarter 2010 Financial Results; Updates Guidance for 2010 3Quest Diagnostics Reports Third Quarter 2010 Financial Results; Updates Guidance for 2010 4Quest Diagnostics Reports Third Quarter 2010 Financial Results; Updates Guidance for 2010 5Quest Diagnostics Reports Third Quarter 2010 Financial Results; Updates Guidance for 2010 6Quest Diagnostics Reports Third Quarter 2010 Financial Results; Updates Guidance for 2010 7Quest Diagnostics Reports Third Quarter 2010 Financial Results; Updates Guidance for 2010 8Quest Diagnostics Reports Third Quarter 2010 Financial Results; Updates Guidance for 2010 9Quest Diagnostics Reports Third Quarter 2010 Financial Results; Updates Guidance for 2010 10Quest Diagnostics Reports Third Quarter 2010 Financial Results; Updates Guidance for 2010 11Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 2Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 3Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 4Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 5Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 6Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 7Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 8
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: